Sunpharma Ltd — Q4 FY25
Sun Pharma reported Q4 FY25 consolidated revenue of INR 12,816 crore, up 8.5% YoY, with EBITDA of INR 3,716 crore (+22.4% YoY) and margin expansion of 340 bps to 28.7%.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
FY25 R&D spend to be less than 7% of sales
Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
Specialty sales growth to normalize after Q3 inventory build
Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1